Switzerland· 67469001
Breyanzi, Suspension
A lisocabtagene maraleucel product containing lisocabtagenum maraleucelum , enthält genetisch modifizierte zellen (cd4+ oder cd8+ komponente, zieldosis 100x10e6 car+ t-zellen in zielverhältnis 1:1 von cd4+ und cd8+ komponenten), registered in Switzerland by Bristol-Myers Squibb SA and dispensed under Swissmedic category A. The same ATC class is registered in 12 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Lisocabtagene maraleucel is registered in 12 of 19 countries.
Countries holding a registration under ATC L01XL08 (lisocabtagene maraleucel), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 8 of them publish a price we can compare per daily dose
Lisocabtagene maraleucel · ATC L01XL08
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
The record
At a glance
Swissmedic (Switzerland)- Active substance
- lisocabtagenum maraleucelum , enthält genetisch modifizierte Zellen (CD4+ oder CD8+ Komponente, Zieldosis 100x10e6 CAR+ T-Zellen in Zielverhältnis 1:1 von CD4+ und CD8+ Komponenten)
- Manufacturer
- Bristol-Myers Squibb SA
- Country
- Switzerland (CH)
- ATC code
- L01XL08
- ATC class
- Lisocabtagene maraleucel
- Swissmedic category
- A
- Reimbursed
- No
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
37 interactions on record for lisocabtagene maraleucel.
Graded by severity as the source publishes them — 21 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lisocabtagene maraleucel · interactions on record
37 records
- 21 severe
- 16 moderate
Most severe, free to view
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- NatalizumabL04AA23severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01XL08
Lisocabtagene maraleucel, as other registers publish it.
- IcelandBreyanziBristol-Myers Squibb Pharma EEIG*
- BelgiumBreyanziBristol-Myers Squibb Pharma
- PolandBreyanziBristol-Myers Squibb Pharma EEIG
- FinlandBreyanziBristol-Myers Squibb Pharma EEIG
- DenmarkBreyanziBristol-Myers Squibb Pharma EEIG
- NorwayBreyanziBristol-Myers Squibb Pharma EEIG
- CanadaBREYANZIBRISTOL-MYERS SQUIBB CANADA
- CzechiaBREYANZIBristol-Myers Squibb Pharma EEIG, Dublin
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0d5dd09e-4c80-41c8-91cc-a1c3ce863d4c GET /v1/drugs/0d5dd09e-4c80-41c8-91cc-a1c3ce863d4c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "swissmedic_auth",
"heilmittelcode": "Transplantat: Gentherapieprodukt"
}See everything about lisocabtagene maraleucel.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.